Add BrightSurf on Google Email

Three-dimensional gene hubs may promote brain cancer

A recent preclinical study from Weill Cornell Medicine researchers suggests that three-dimensional gene hubs may promote brain cancer. The findings, published in Molecular Cell, offer a new way to think about cancer beyond gene mutations and highlight the importance of understanding DNA organization in tumor cells.

SourceWeill Cornell Medicine·JournalMolecular Cell·DateApr 22, 2025

Test predicts which patients with prostate cancer are most likely to develop long-term side effects from radiation therapy

A UCLA study validates the predictive power of PROSTOX, a genetic test that uses microRNAs to identify patients at higher risk of developing long-lasting urinary side effects from radiation therapy. The test helps doctors and patients choose safer treatment options, reducing the burden of long-term complications.

SourceUniversity of California - Los Angeles Health Sciences·JournalClinical Cancer Research·DateApr 7, 2025

High resolution ultrasound could enable faster prostate cancer diagnosis

A new study has shown that high-resolution ultrasound can diagnose prostate cancer as effectively as MRI, with improved resolution and lower costs. The technology, called micro-ultrasound, is expected to speed up diagnosis, reduce hospital visits, and make imaging more accessible, particularly in less developed healthcare systems.

SourceEuropean Association of Urology·JournalJAMA·TypeRandomized controlled/clinical trial·DateMar 23, 2025

Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer

A new study confirms that a shorter, higher-dose-per-day radiation course is as effective as conventional radiotherapy for treating early-stage prostate cancer without increasing side effects. The study found similar cancer control rates and fewer gastrointestinal issues with the new approach.

Study reveals hope for immunotherapy as prostate cancer treatment

Researchers at University of Arizona Cancer Center found that an immunotherapy previously shown to be ineffective against prostate cancer may have therapeutic potential when combined with a specific protein inhibitor. The study's co-author, Noel Warfel, PhD, identified a way to sensitize prostate tumors to immune checkpoint inhibitors ...

SourceUniversity of Arizona Health Sciences·JournalCancer Immunology Research·TypeExperimental study·DateMar 4, 2025

A protein from tiny tardigrades may help cancer patients tolerate radiation therapy

Researchers have developed a new strategy to protect cancer patients from radiation-induced DNA damage using a protein from tardigrades. The approach makes use of messenger RNA encoding the protein, which is delivered to patient tissues before radiation treatment. This reduces double-stranded DNA breaks by 50% in mouse models.

SourceMassachusetts Institute of Technology·JournalNature Biomedical Engineering·DateFeb 26, 2025

New laparoscopic imaging technique accurately maps biological tissue for minimally invasive surgery

A new laparoscopic imaging technique uses stereo depth estimation and speckle-illumination SFDI to accurately map the optical properties of biological tissue. The device provides detailed optical property maps, enabling surgeons to identify critical tumor margins and improve clinical outcomes.

SourceSPIE--International Society for Optics and Photonics·JournalJournal of Biomedical Optics·DateFeb 17, 2025

UCLA-led study establishes link between early side effects from prostate cancer radiation and long-term side effects

A recent study published in Lancet Oncology reveals a significant link between early side effects from radiation therapy for prostate cancer and long-term complications. Men who experience moderate acute urinary or bowel side effects during treatment are nearly twice as likely to develop late urinary or bowel issues, respectively. This...

PROTAC technology for prostate cancer treatment

The latest therapeutic strategies for castration-resistant prostate cancer focus on innovative proteolysis-targeting chimera (PROTAC) technology, which degrades target proteins and holds potential as effective treatments. PROTAC technology is a novel means to combat resistance mechanisms in PRPC.

SourceCompuscript Ltd·JournalActa Materia Medica·DateJan 30, 2025

Gene classifier tests for prostate cancer may influence treatment decisions despite lack of evidence for long-term outcomes

A systematic review found that genomic classifier tests can influence risk classifications and treatment decisions for patients with localized prostate cancer, but more research is needed to understand their cost-effectiveness and impact on racial groups. The tests may lead to more conservative management options, such as active survei...

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeNews article·DateJan 20, 2025

Research Spotlight: Lipid nanoparticle therapy developed to stop tumor growth and restore tumor suppression

Researchers developed a novel approach using lipid nanoparticles to deliver mRNA and siRNA, restoring tumor suppressors and inhibiting tumor drivers in prostate cancer cells. This technique holds promise for treating various types of cancer by targeting specific pathways related to tumor growth and suppression.

SourceMass General Brigham·JournalACS Nanoscience Au·TypeExperimental study·DateJan 9, 2025

Advanced imaging uncovers hidden metastases in high-risk prostate cancer cases

A new study found that nearly half of high-risk prostate cancer patients have metastatic disease when evaluated with advanced PSMA-PET imaging, suggesting traditional imaging may underestimate cancer spread. This challenge the interpretation of previous studies like EMBARK trial, and support the inclusion of PSMA-PET for patient select...

Treating prostate cancer with novel platinum complex via targeting androgen receptor signaling

Researchers discovered a novel platinum complex that targets androgen receptor signaling, inhibiting cell growth and survival in prostate cancer cells. The complex, 5-H-Y, showed stronger cytotoxic effects than cisplatin with minimal toxicity, offering a promising approach to treating advanced prostate cancer.

SourceShibaura Institute of Technology·JournalInorganic Chemistry·TypeExperimental study·DateDec 16, 2024

Study finds new blood test predicts prognosis for advanced prostate cancer patients

A new DNA sequencing test called AR-ctDETECT has been found to distinguish between patients with poor and favorable prognoses in advanced prostate cancer. The test identified circulating tumor DNA in 59% of patients and showed that detectable ctDNA was associated with worse overall survival.

SourceUniversity of Minnesota Medical School·JournalNature Communications·TypeRandomized controlled/clinical trial·DateDec 11, 2024

Discovery may open new way to attack prostate cancer

Researchers activate glycoprotein 130 and its associated signaling pathway to slow down tumor growth in prostate cancer, stimulating immune system to fight tumour cells. Studies of tissue samples from prostate cancer patients show positive correlation with better survival rates.

SourceUmea University·JournalMolecular Cancer·TypeExperimental study·DateDec 3, 2024